

## Editorials

- Education in Musculoskeletal Health — How Can It Be Improved to Meet Growing Needs?**  
*A.D. Woolf, K. Åkesson* . . . . . 455
- Curriculum Design: Finding a Balance**  
*L.J. Albert* . . . . . 458
- Rheumatoid Arthritis and Diabetes Mellitus: Evidence for an Association?**  
*M. Doran* . . . . . 460
- Is Minimal Clinically Important Difference Relevant for the Interpretation of Clinical Trials in Pediatric Rheumatic Diseases?**  
*N. Ruperto* . . . . . 463
- Role of Thrombotic and Fibrinolytic Alterations in the Pathogenesis and Treatment of Osteonecrosis**  
*M.A. Mont, S.D. Ulrich, T.M. Seyler* . . . . . 466

## Articles

- Prevalent RA and Diabetes Among NHANES III Participants Aged 60 and Older**  
*J.F. Simard, M.A. Mittleman* . . . . . 469
- Infliximab Does Not Suppress the Tuberculin Skin Test (PPD)** *G. Hatemi, M. Melikoglu, I. Fresko, S. Masatlioglu, K. Tascilar, H. Yazici* . . . . . 474
- Work Disability in RA — Development Over 15 Years and Evaluation of Predictive Factors Over Time**  
*K. Eberhardt, B-M. Larsson, K. Nived, E. Lindqvist* . . 481
- Hypothesis Adipose Tissue as a Modulator of Clinical Inflammation: Does Obesity Reduce the Prevalence of RA?**  
*T. Bartfai, J. Waalen, J.N. Buxbaum* . . . . . 488
- Toll-like Receptor Expression in Lupus PBMC**  
*K. Migita, T. Miyashita, Y. Maeda, et al* . . . . . 493
- Outcome Measurements in Scleroderma: Results from a Delphi Exercise**  
*H. Gazi, J.E. Pope, P. Clements, et al* . . . . . 501
- Safety and Efficacy of Readministration of Infliximab After Longterm Continuous Therapy and Withdrawal in Patients with AS**  
*X. Baraliakos, J. Listing, M. Rudwaleit, et al* . . . . . 510

**Low Molecular Weight Phenotype of Apo(a) Is a Risk Factor of Corticosteroid-Induced Osteonecrosis of the Femoral Head After Renal Transplant**

*T. Hirata, M. Fujioka, K.A. Takahashi, et al* . . . . . 516

**Adenoviral Gene Transfer of the Endogenous Inhibitor I $\kappa$ B $\alpha$  into Human OA Synovial Fibroblasts Demonstrates That Several MMP and Aggrecanases Are NF- $\kappa$ B-Dependent**

*J. Bondeson, S. Lauder, S. Wainwright, et al* . . . . . 523

**A Model to Estimate HUI3 Utility Scores from WOMAC Index Scores in Patients with OA of the Knee**

*P. Grootendorst, D. Marshall, D. Pericak, N. Bellamy, D. Feeny, G.W. Torrance* . . . . . 534

**Tramadol for OA: A Systematic Review and Metaanalysis**

*M.S. Cepeda, F. Camargo, C. Zea, L. Valencia* . . . . 543

**Cyclic Compression Loaded on Cartilage Explants Enhances the Production of ROS**

*T. Tomiyama, K. Fukuda, K. Yamazaki, et al* . . . . . 556

**Evaluation of the Activity of an Academic Rheumatology Consult Service Over 10 Years: Using Data to Shape Curriculum**

*K. Ta, G.C. Gardner* . . . . . 563

**Canadian Multidisciplinary Core Curriculum for Musculoskeletal Health**

*V.M.R. Wadey, E. Tang, G. Abelseth, P. Dev, R.A. Olshen, D. Walker* . . . . . 567

## Pediatric Rheumatology

**The Quality of My Life Questionnaire: The Minimal Clinically Important Difference for Pediatric Rheumatology Patients**

*G.W.K. Gong, N.L. Young, H. Dempster, M. Porepa, B.M. Feldman* . . . . . 581

## Case Report

**Mycophenolate Mofetil and IV Dexamethasone in the Treatment of Persistent Lupus Myelitis**

*P. Tomietto, S. D'Agostini, V. Annese, S. De Vita, G. Ferraccioli* . . . . . 588

**Rapid Acetabular Osteolysis Secondary to Subchondral Insufficiency Fracture**

*T. Yamamoto, R. Schneider, Y. Iwamoto, P.G. Bullough* . . . . . 592

*Contents continued opposite inside back cover . . .*

---

## Images in Rheumatology

Joint Destruction in Septic Arthritis *I. Uthman* . . . 596

## OMERACT 8

International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials, St. Julian's Bay, Malta, May 10-14, 2006

Introduction *M. Boers, V. Strand, L.S. Simon, P. Tugwell, P. Brooks* . . . . . 599

## Biomarkers and Surrogate Endpoints

The WHO International Classification of Functioning, Disability and Health: A Conceptual Model and Interface for the OMERACT Process *G. Stucki, A. Boonen, P. Tugwell, A. Cieza, M. Boers* . . . . . 600

Definitions and Validation Criteria for Biomarkers and Surrogate Endpoints: Development and Testing of a Quantitative Hierarchical Levels of Evidence Schema *M.N. Lassere, K.R. Johnson, M. Boers, et al* . . . . . 607

Simulation Studies of Surrogate Endpoint Validation Using Single Trial and Multitrial Statistical Approaches *M. Lassere, K. Johnson, M. Hughes, et al.* . . . . . 616

Synovial Macrophages as a Biomarker of Response to Therapeutic Intervention in RA: Standardization and Consistency Across Centers *B. Bresnihan, D.M. Gerlag, T. Rooney, et al* . . . . . 620

Testing of the Preliminary OMERACT Validation Criteria for a Biomarker to Be Regarded as Reflecting Structural Damage Endpoints in RA Clinical Trials: The Example of CRP *S.O. Keeling, R. Landewé, D. van der Heijde, et al.* . . . . . 623

Development of Draft Validation Criteria for a Soluble Biomarker to Be Regarded as a Valid Biomarker Reflecting Structural Damage Endpoints in RA and SpA Clinical Trials *W.P. Maksymowych, R. Landewé, M. Boers, et al.* . 634

Assessing Single Joints in Arthritis Clinical Trials *J.T. Giles, P. Mease, M. Boers, et al.* . . . . . 641

## Letters

Sarcoid-like Granulomatous Disease Following Etanercept Treatment for RA *A. Kudrin, E.R. Chilvers, A. Ginawi, et al.* . . . . . 648

CRP in Primary Antiphospholipid Syndrome *P.R.J. Ames, C. Tommasino, V. Brancaccio, A. Ciampa* . . . . . 650

Meetings in Rheumatology . . . . .